Regeneron Pharmaceuticals, Inc. (REGN) Receives $469.95 Average Target Price from Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned a consensus recommendation of “Hold” from the thirty-one ratings firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, sixteen have issued a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $465.40.

A number of equities research analysts recently weighed in on REGN shares. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group reaffirmed a “hold” rating and set a $500.00 price target (up from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, September 29th. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Finally, Evercore ISI lowered their price target on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th.

In other news, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares in the company, valued at $5,060,204.94. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,352 shares of company stock worth $2,037,772. Insiders own 10.80% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio increased its holdings in shares of Regeneron Pharmaceuticals by 0.4% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 54,532 shares of the biopharmaceutical company’s stock worth $24,382,000 after acquiring an additional 244 shares during the period. Americafirst Capital Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $700,000. Moors & Cabot Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $217,000. IFM Investors Pty Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $979,000. Finally, Fieldpoint Private Securities LLC increased its holdings in shares of Regeneron Pharmaceuticals by 285.3% in the 3rd quarter. Fieldpoint Private Securities LLC now owns 1,021 shares of the biopharmaceutical company’s stock worth $457,000 after acquiring an additional 756 shares during the period. 69.47% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals (REGN) traded up $11.61 during trading on Thursday, hitting $373.47. 1,799,404 shares of the stock traded hands, compared to its average volume of 954,248. Regeneron Pharmaceuticals has a 52 week low of $340.09 and a 52 week high of $543.55. The firm has a market capitalization of $40,125.25, a price-to-earnings ratio of 32.34, a P/E/G ratio of 1.47 and a beta of 1.54. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business’s revenue was up 23.0% on a year-over-year basis. During the same period last year, the business earned $3.13 EPS. sell-side analysts forecast that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Receives $469.95 Average Target Price from Brokerages” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.com-unik.info/2017/12/03/regeneron-pharmaceuticals-inc-regn-receives-469-95-average-target-price-from-brokerages.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit